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Abstract
 
PD-1 is an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid
cells. Mice deficient in 
 
PD-1
 
 exhibit a breakdown of peripheral tolerance and demonstrate
multiple autoimmune features. We report here that the ligand of 
 
PD-1
 
 (
 
PD-L1
 
) is a member of
the B7 gene family. Engagement of 
 
PD-1
 
 by PD-L1 leads to the inhibition of T cell receptor–
mediated lymphocyte proliferation and cytokine secretion. In addition, 
 
PD-1
 
 signaling can in-
hibit at least suboptimal levels of CD28-mediated costimulation. 
 
PD-L1
 
 is expressed by anti-
gen-presenting cells, including human peripheral blood monocytes stimulated with interferon
 
g
 
, and activated human and murine dendritic cells. In addition, 
 
PD-L1
 
 is expressed in nonlym-
phoid tissues such as heart and lung. The relative levels of inhibitory PD-L1 and costimulatory
B7-1/B7-2 signals on antigen-presenting cells may determine the extent of T cell activation
and consequently the threshold between tolerance and autoimmunity. 
 
PD-L1
 
 expression on
nonlymphoid tissues and its potential interaction with 
 
PD-1
 
 may subsequently determine the
extent of immune responses at sites of inflammation.
Key words: binding • proliferation inhibition • cytokine secretion inhibition • tissue 
expression • peripheral tolerance
 
Introduction
 
The balance of positive and negative signals is of central
importance in maximizing the ability of the adaptive im-
mune response to defend the host while maintaining im-
munologic tolerance and preventing autoimmunity. PD-1
is a type I transmembrane protein that is transcriptionally
induced in activated T cells, B cells (1–3), and myeloid cells
(Nishimura, H., and T. Honjo, unpublished data). The ex-
tracellular region of PD-1 consists of a single Ig-like vari-
able (IgV)
 
1
 
 domain (4), and the cytoplasmic region contains
an immunoreceptor tyrosine-based inhibitory motif (for a
review, see reference 5). Recent work has revealed that the
PD-1 receptor acts to downregulate immune responses and
its loss leads to a breakdown of peripheral tolerance. Mice
deficient in 
 
PD-1
 
 develop lupus-like proliferative arthritis
and glomerulonephritis with predominant IgG3 deposition
as they age (6). Additionally, in a manner similar to that re-
ported in the lupus-prone MRL mice, introduction of the
 
lpr
 
 mutation leads to accelerated disease onset and severity
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of symptoms. Furthermore, 2C-TCR (anti–H-2L
 
d
 
) trans-
genic mice homozygous for the 
 
PD-1
 
 null mutation in the
autoreactive H-2
 
b/d
 
 background develop a chronic graft-
versus-host–like disease (6). In this model, peripheral 2C T
cells show a memory rather than a naive phenotype and in-
filtrate into tissues including the epidermis, despite efficient
negative selection in the thymus. However, it remains to
be determined whether this regulation is achieved at the
activation phase (lymph nodes), at the effector phase (tis-
sues), or both. Direct approaches to this question as well as
further characterization of this inhibitory pathway have
been hampered by a lack of knowledge of the identity of
the ligand for PD-1.
 
PD-1
 
 is structurally similar to CTL-associated antigen 4
(
 
CTLA-4
 
), which binds B7-1 and B7-2 and plays a crucial
role for the maintenance of T cell homeostasis (for reviews,
see references 7 and 8). Although PD-1 does not have the
MYPPPY motif that is critical for B7-1 and B7-2 binding,
the extracellular regions of PD-1 and CTLA-4 each consist
of a single IgV domain, with 23% identity to each other.
This is in comparison to the 
 
z
 
30% identity between
CTLA-4 and CD28 (9). Thus, we reasoned that the ligand
of PD-1 might be structurally related to B7-1 and B7-2.
We have pursued this hypothesis by searching for B7-like
molecules and testing their binding to PD-1. In this work,
we identify a ligand of PD-1 and demonstrate that this re-
ceptor–ligand interaction leads to the inhibition of lym-
phocyte proliferation.
 
Materials and Methods
 
Molecular Cloning.
 
A BLAST search of the human expressed
sequence tag (EST) database of the National Center for Biotech-
nology Information (http://www.ncbi.nlm.nih.gov) identified
two overlapping ESTs with homology to 
 
B7-1
 
 and 
 
B7-2
 
(AA292201 and AA399416). A 389-bp portion of the cDNA was
amplified by PCR using as primers 5
 
9
 
-dCAGCTATGGTGGT-
GCCGACTACAA-3
 
9
 
 and 5
 
9
 
-dAGGTGCTAGGGGACAGT-
GTTAGACA-3
 
9
 
. The PCR product was biotin labeled and used
to isolate a full-length cDNA by Cloncapture (CLONTECH
Laboratories, Inc.) from a human placenta cDNA library in the
pAXEF vector (10). A search of the National Center for Biotech-
nology Information murine EST database identified overlapping
sequences with homology to human PD-1 ligand 1 (
 
PD-L1
 
;
AA896104 and AA823166). A 409-bp portion was amplified by
PCR using as primers 5
 
9
 
-dGAGAGCCTCGCGTCCAAAG-3
 
9
 
and 5
 
9
 
-dGTGGTTTTGCCCTGGCTGTGATCT-3
 
9
 
. The
PCR product was biotin labeled and used to isolate a full-length
cDNA by Cloncapture (CLONTECH Laboratories, Inc.) from a
murine-activated T cell cDNA library in the pAXEF vector.
 
Fusion Proteins and Cell Transfections.
 
The Ig fusion proteins
used consist of the complete extracellular region of a receptor
linked to the hinge-C
 
H
 
2-C
 
H
 
3 domains of either human Ig
 
g
 
1 or
the same domains of murine Ig
 
g
 
2a (with four point mutations
blocking Fc receptor and complement binding) to give Ig(
 
g
 
1)
and Ig(
 
g
 
2a) fusions, respectively (11). These recombinant pro-
teins were produced in COS cells transiently transfected with Li-
pofectAMINE (GIBCO BRL) or stably transfected Chinese
hamster ovary (CHO) cell lines and purified from conditioned
media using protein A–Sepharose.
 
The human 
 
PD-L1
 
 cDNA was subcloned into pEF6 (Invitro-
gen) and linearized with ScaI. This DNA was coelectroporated
into CHO-K1 cells with a plasmid construct containing a hygro-
mycin B resistance gene under the control of a phosphoglycerate
kinase gene promoter. Cells were selected in 800 
 
m
 
g/ml hygro-
mycin B and cloned by limiting dilution. The murine 
 
PD-L1
 
cDNA in pAXEF was linearized with ApaLI and coelectroporated
into CHO-K1 cells with a puromycin resistance gene under the
control of a phosphoglycerate kinase gene promoter. Cells were
selected in 10 
 
m
 
g/ml puromycin and cloned by limiting dilution.
 
Murine T Cell Assays.
 
Splenic T cells were collected by anti-
IgM panning from pools of splenocytes from two to three age-
matched C57BL/6 and C57BL/6–
 
PD-1
 
2
 
/
 
2
 
 mice, resulting in
80% purity. 4 
 
3
 
 10
 
4
 
 cells/well in 96 U-bottomed plates (Iwaki)
were incubated with the indicated concentrations of reagents.
Purified anti–mouse CD3 (145-2C11) alone or in combination
with hPD-L.Ig(
 
g
 
2a) or mouse IgG2a were precoated overnight
at 4
 
8
 
C. Cells were cultured for 72 h, then pulsed with 0.5 
 
m
 
Ci of
[
 
3
 
H]thymidine (Amersham Pharmacia Biotech) per well for the
last 18 h, and incorporated label was measured.
 
Human T Cell Proliferation and Cytokine Assays.
 
PBMCs were
isolated by Ficoll-Hypaque gradient centrifugation. CD4
 
1
 
 T cell
populations (85–90% purity) were purified by negative selection
using a cocktail of mAbs and immunomagnetic beads (PerSeptive
Biosystems). Anti-CD3, control IgG, and fusion protein were
covalently attached to polyurethane-coated tosyl-activated Dyna-
beads (Dynal) according to the manufacturer’s instructions and as
described previously (12). Anti-CD3 Ab (UCHT1; BD Phar-
Mingen) at the indicated concentration was added to 10
 
7
 
 beads/ml
in 0.1 M phosphate buffer, pH 7.4. Control IgG was added to the
bead suspension in order to maintain a constant total Ig concen-
tration of 5 
 
m
 
g/ml during binding. Similarly, anti–CD3/hPD-
L.Ig(
 
g
 
2a) beads were prepared with the indicated anti-CD3 Ab
concentration, a constant concentration of either hPD-L1.Ig rep-
resenting 40% of the total bound protein (2 
 
m
 
g/10
 
7
 
 beads), or
control IgG to make up the remaining total bound protein. 10
 
5
 
 T
cells were cultured in 96-well flat-bottomed plates, and beads
were added at a 1:1 bead/cell ratio in the presence or absence of
the indicated concentrations of anti-CD28 Ab (CD28.2; BD
PharMingen). Proliferation was determined by labeling cultures
for the last 6 h of a 4-d assay with 1 
 
m
 
Ci [
 
3
 
H]thymidine/well. For
analysis by cytokine ELISAs, cultures were set up as described
above and supernatants were harvested at the indicated times.
IFN-
 
g
 
, IL-10, and IL-2 concentrations were determined using
commercially available ELISA kits (Genzyme).
 
Dendritic Cell Isolation.
 
Human dendritic cells were derived
from peripheral blood. Mononuclear cells were isolated after
fractionation on a Ficoll gradient. Nonadherent cells were re-
moved and the remaining cells were cultured in 150 ng/ml hu-
man GM-CSF (R & D Systems) and 100 ng/ml human IL-4
(R & D Systems) for 2 d. The nonadherent dendritic cells were
isolated (CD80
 
1
 
CD86
 
1
 
HLA-DR
 
1
 
CD54
 
1
 
CD58
 
1
 
CD1a
 
1
 
) and cul-
tured in GM-CSF alone or activated with GM-CSF, 2.5 
 
m
 
g/ml
LPS (Sigma-Aldrich), and 10 ng/ml human IFN-
 
g
 
. At 4 and 20 h
after activation, cells were harvested and RNA was isolated using
the RNeasy kit (QIAGEN).
Murine bone marrow mononuclear cells were immunode-
pleted of granulocytes, lymphocytes, and Ia
 
1
 
 cells by magnetic-
activated cell sorting and cultured in petri dishes with GM-CSF
and IL-4. Dendritic cells were harvested as the nonadherent pop-
ulation after 7 d of culture, and demonstrated to be 75–80%
CD11c
 
1
 
, high Ia
 
1
 
 cells. Cells were activated with LPS and hu-
man IFN-
 
g
 
. 
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RNA Expression Analysis.
 
For quantitative PCR analysis, cel-
lular RNA was deoxyribonuclease treated, reextracted, and con-
verted to first strand cDNA. 6-carboxyfluorescein (FAM)-labeled
hPD-L1, hB7-1, hB7-2, and human glyceraldehyde 3-phosphate
dehydrogenase (hGAPDH) probes were purchased from PE Bio-
systems (hPD-L1: 5
 
9
 
-dGCCGAAGTCATCTGGACAAG-3
 
9
 
and 5
 
9
 
-dTCTCAGTGTGCTGGTCACAT-3
 
9
 
, probe 5
 
9
 
-FAM-
dCACCACCACCAATTCCAAGA-3
 
9
 
; hB7-1: 5
 
9
 
-dACGT-
GACCAAGGAAGTGAAAGAA-3
 
9
 
 and 5
 
9
 
-dTGCCAGCTCT-
TCAACAGAAACAT-3
 
9
 
, probe 5
 
9
 
-FAM-dTGGCAACGCT-
GTCCTGTGGTCAC-3
 
9
 
; and hB7-2: 5
 
9
 
-dGGGCCGCACA-
AGTTTTGAT-3
 
9
 
 and 5
 
9-dGCCCTTGTCCTTGATCTGA-
AGA-39, probe 59-FAM-dCGGACAGTTGGACCCTGAGA-
CTTCACA-39.
PCR reactions were set up in 96-well plates using reagents
from the PerkinElmer TaqMan™ EZ kit, according to the man-
ufacturer’s instructions. Standard curves were set up for each of
the four genes analyzed. 40 cycles of PCR were run in an ABI
Prism 7700 Sequence Detector (PerkinElmer) and GAPDH was
used to normalize the PD-L1, B7-1, and B7-2 results.
The Mu19KsubA chip (Affymetrix) was used for GeneChip®
hybridization analysis. The sequence of a portion of murine
PD-L1 is represented by the EST TC17781 of The Institute for
Genomic Research (http://www.tigr.org) on this chip. RNA
isolation, chip hybridization, and scanning were performed as de-
scribed (13).
For RNA blot hybridization, the 1.6-kb human and 3.6-kb
murine PD-L1 cDNAs were excised by digestion with XbaI and
labeled by random priming with [g-32P]ATP and the Klenow
fragment of DNA polymerase I. RNA blots were hybridized as
described (14).
Chromosomal Analysis. The chromosomal location of the hu-
man PD-L1 gene was identified using monochromosomal so-
matic cell hybrid DNA templates (Quantum Technologies) for
PCR amplification using PD-L1–specific primers. The oligonu-
cleotide primers used were: 59-dCCCAGGTAATATTCT-
GAATGTGTC-39  and 59-dATTCCATAAATATCTGCTGA-
ATGT-39. Each PCR used 100 ng of template DNA, with 30
cycles of 948C, 30 s; 608C, 30 s; and 688C, 60 s. The PCR prod-
ucts were analyzed by agarose gel electrophoresis and ethidium
bromide staining.
Results
Identification of a Novel B7 Homologue That Binds PD-1.
The human and murine PD-L1 cDNAs were identified in
a B7 homology–based search of EST databases. A BLAST
search of the National Center for Biotechnology Informa-
tion database revealed two human overlapping ESTs with
similarity to B7-1 and B7-2 molecules (accession nos.
AA292201 and AA399416). Using these sequences, a full-
length cDNA was isolated from a human placenta cDNA
library. In parallel, two murine ESTs were found that cor-
respond to the murine orthologue of PD-L1 (accession
nos. AA896104 and AA823166). Using these sequences, a
full-length cDNA was isolated from a murine activated T
cell cDNA library. Human and mouse PD-L1 molecules
are members of the B7 gene family and share a common
structural organization consisting of an IgV and an IgC do-
main in the extracellular region (15), with a hydrophobic
transmembrane domain followed by a short, charged intra-
cellular region (Fig. 1). Human PD-L1 with 290 residues is
identical to B7-H1, which was reported to have T cell
stimulation activities (16). Murine PD-L1 cDNA encodes a
polypeptide with 70% amino acid identity to its human
orthologue (Fig. 1). PD-L1 has amino acid identities of 21,
20, and 23% to B7-1, B7-2, and the ligand of inducible co-
stimulator (ICOS), respectively (11, 15, 17, 18).
The ability of PD-L1 to bind PD-1 has been determined
by flow cytometry and BIAcore binding assays. Human and
murine PD-1.Ig fusion proteins bound to both human and
murine PD-L1 expressed on CHO cells as detected by flow
cytometry (Fig. 2 A). However, neither human CTLA-
4.Ig, human CD28.Ig, or human ICOS.Ig bound to either
PD-L1–expressing line. The PD-1 fusion proteins did not
bind CHO cells transfected with vector alone. Further
confirmation of the PD-1–PD-L1 interaction was obtained
using surface plasmon resonance with a BIAcore instru-
ment. The human and murine PD-1.Ig proteins and hu-
man CTLA-4.Ig were immobilized on the flow cell sur-
faces of a dextran chip, and tested for binding to soluble
human PD-L1.Ig. PD-L1.Ig bound to both human and
murine PD-1.Ig but not to human CTLA-4.Ig (Fig. 2 B).
This binding was blocked by competition with coinjected
soluble PD-1.Ig but not CTLA-4.Ig. Soluble forms of hu-
Figure 1. Amino acid sequence alignment of murine and human B7
gene family members. Identical amino acids are boxed in black and con-
servative substitutions in gray. Predicted signal and transmembrane do-
mains of PD-L1 are underlined. Amino acids comprising the binding site
of human B7-1 are indicated with a dot (reference 26). The sequences of
the human (reference 11) and murine (references 17 and 18) ligands of
ICOS (ICOS-L) have been reported previously. The full-length cDNA
sequences of the human and murine PD-L1 cDNAs have been deposited
with EMBL/GenBank/DDBS under accession nos. AF233516 and
AF233517, respectively.1030 PD-1 Ligand 1 Inhibits T Cell Activation
man B7-1 and B7-2 did not bind immobilized human PD-
1.Ig (data not shown).
PD-L1, B7-1, and B7-2 Are Coexpressed on Antigen-pre-
senting Cells. We next examined the pattern of PD-L1
expression on antigen-presenting cells and compared it
with that of B7-1 and B7-2 expression. First, we analyzed
expression in human blood monocytes by RNA blot hy-
bridization and found that PD-L1 is not expressed by un-
stimulated monocytes, but is rapidly upregulated upon
IFN-g treatment (Fig. 3 A). Treatment of monocytes with
another proinflammatory cytokine, TNF-a, led to a low
level induction similar to that found with medium alone,
presumably as a result of activation by adherence to plastic
(Fig. 3 A). In addition to the major 4.2-kb PD-L1 mRNA,
we also observed a minor 1.8-kb PD-L1 mRNA species in
IFN-g–treated monocytes. The major 4.2-kb mRNA spe-
cies has also been reported by Dong et al. (16). We also de-
tected expression of PD-L1 by human B cells activated by
cell surface Ig cross-linking, but not by the Raji cell line
(Fig. 3 A). Similarly, B7-1 is not expressed by unstimulated
monocytes but is upregulated in response to IFN-g with
similar kinetics to PD-L1 expression.  In contrast, B7-2
mRNA is constitutively expressed in monocytes and levels
are unaffected by IFN-g or TNF-a.
Second, PD-L1, B7-1, and B7-2 mRNA expression by
human dendritic cells was examined by quantitative PCR.
Human peripheral blood–derived dendritic cells were
treated with GM-CSF alone or activated with GM-CSF,
LPS, and IFN-g. As a result of activation by LPS and IFN-g,
PD-L1 mRNA was rapidly induced with a 16-fold in-
crease at 4 h and a 34-fold increase at 20 h relative to non-
induced cells (Fig. 3 B). B7-1 and B7-2 mRNAs were also
induced upon activation: B7-1 was induced 21-fold at 4 h
and 22-fold at 20 h. B7-2 showed little induction at 4 h;
however, expression was induced fivefold at 20 h (Fig. 3
B). Expression of PD-L1 by murine bone marrow–derived
dendritic cells treated with LPS and IFN-g was examined
using GeneChip® hybridization. PD-L1 expression in these
cells follows a pattern similar to that observed on human
dendritic cells: a fivefold induction of the PD-L1 mRNA
relative to the uninduced cells at 6 and 20 h after induction
(data not shown). These data demonstrate that PD-L1 is
expressed by antigen-presenting cells and lymphocytes, and
it is induced on dendritic cells in a manner similar to B7-1
and B7-2. We also demonstrated an induction of PD-L1 by
treatment of human keratinocytes with phorbol ester and
IFN-g (Fig. 3 C).
In murine tissues, we found an z3.7-kb PD-L1 mRNA
transcript by Northern blot hybridization. Dong et al. (16)
have reported a 4.2-kb PD-L1 (B7-H1) mRNA species in
normal human tissue RNA. The distribution of the murine
PD-L1 mRNA closely resembled that of the human with
high levels in the heart, thymus, and lung, and low levels in
the kidney, spleen, and liver (Fig. 3 D).
By PCR of monochromosomal human somatic cell hy-
brids, we demonstrated that the human PD-L1 gene is lo-
cated on chromosome 9 (Fig. 3 E), unlike the B7-1 and
B7-2 genes, which are clustered on chromosome 3 (19).
Thus, the parallel upregulation we observe for these genes
on activated dendritic cells is not the result of clustering at a
single chromosomal site. In addition, this also distinguishes
PD-L1 from the B7-like butyrophilins, which are in the
MHC gene complex of human chromosome 6 (20).
PD-1–PD-L1 Interaction Inhibits CD3-mediated T Cell
Proliferation. To examine the functional significance of the
PD-1–PD-L1 interaction, we compared the effect of PD-
L1.Ig on the proliferation of murine T cells derived from
wild-type and PD-1–deficient mice (21). We first exam-
Figure 2. The binding of PD-1 to PD-L1. (A) CHO cells stably transfected with human or murine PD-L1 or vector alone were stained with hPD-
1.Ig(g2a), mPD-1.Ig(g1), hCTLA-4.Ig(g2a), hCD28.Ig(g1), or hICOS.Ig(g2a) (species matched), and developed with goat anti–murine IgG2a-PE or
anti–human IgG-FITC antisera. (B) PD-L1.Ig was tested for binding to immobilized mPD-1.Ig(g1) (gray bars), hPD-1.Ig(g1) (black bars), and hCTLA-
4.Ig(g1) (white bars) using surface plasmon resonance on a BIAcore 2000 instrument. Receptor-Fc fusion proteins were immobilized on a CM5 dextran
chip by amine coupling with normal human serum/N-ethyl-N9-(dimethylamino)propyl I carbodiimide hydrochloride (EDC) in 10 mM sodium acetate,
pH 4.0, as described (reference 27). The amounts of protein immobilized were 5,383 response units (RU) for mPD-1.Ig(g1), 5,416 RU for hPD-
1.Ig(g1), and 11,493 RU for hCTLA-4.Ig(g1). Concentrated COS-conditioned medium from hPD-L1.Ig(g2a)–transfected cells was analyzed with (1)
or without (2) coinjection of 100 mg/ml of soluble mPD-1.Ig, hPD-1.Ig, or hCTLA-4.Ig for competition. Binding was quantified as an increase in RU
at 60 s after the end of injection compared with a baseline established 20 s before injection.1031 Freeman et al.
ined the proliferation of purified splenic T cells from wild-
type and PD-12/2 mice to anti-CD3 mAb and found they
were essentially identical (Fig. 4 A). Thus, the loss of PD-1
did not impair the ability of T cells to respond to stimula-
tion through the TCR, nor did it confer a hyperprolifera-
tive phenotype in a primary stimulation. To examine the
effects of PD-L1, an optimal concentration of anti-CD3
mAb and varying concentrations of human PD-L1.Ig or an
IgG control were precoated on plastic plates. Proliferation
of purified splenic T cells was measured 3 d after stimula-
tion by incorporation of [3H]thymidine. As shown in Fig. 4
B, human PD-L1.Ig inhibited proliferation of PD-11/1 T
cells in a dose-dependent fashion relative to the IgG control
(Fig. 4 B). In contrast, human PD-L1.Ig had no effect on
the proliferation of PD-12/2 T cells under the same condi-
tions. These results show that PD-L1 can attenuate TCR-
mediated T cell proliferation. Furthermore, the failure of
PD-L1 to inhibit PD-1–deficient T cells indicates that PD-
L1 conveys this signal via its interaction with PD-1.
The functional consequences of PD-L1 interaction with
its receptor were also examined using human T cells. Puri-
fied CD41 T cells obtained from PBMCs were activated
with beads coated with anti-CD3 mAb and either human
PD-L1.Ig or a control Ig. Proliferation and cytokine pro-
duction were assessed 96 h after stimulation. As shown in
Fig. 4 C, cells activated with anti-CD3 mAb/PD-L1.Ig–
coated beads showed a 69% decrease in proliferation rela-
tive to anti-CD3 mAb/control Ig–activated cells. Further-
more, activation of cells in the presence of PD-L1 also
impairs cytokine secretion. In the presence of PD-L1, the
Figure 3. Expression of PD-L1 in antigen-presenting cells and murine tissues. (A) Northern blot analysis of total RNA of human peripheral blood
monocytes stimulated with 500 U/ml human IFN-g, 100 U/ml human TNF-a, or media alone, and anti-Ig–activated human B cells, with human PD-
L1, B7-1, B7-2, and b-actin cDNA probes. Cells were prepared and stimulated as described (reference 28). Act.B, actinomycin B. (B) Isolated human
peripheral blood dendritic cells (DC) were cultured in either human GM-CSF alone (gray bars) or in GM-CSF, LPS, and IFN-g (black bars) for 4 or 20
h, after which RNA was isolated for quantitative (real time) PCR analysis. Fluorescence is plotted as a ratio of PD-L1, B7-1, or B7-2 signal to the
GAPDH signal. (C) Northern blot analysis of human keratinocyte total RNA with a human PD-L1 cDNA probe. Keratinocytes were isolated and acti-
vated with PMA and IFN-g, as described previously (reference 10). (D) Northern blot analysis of murine tissue polyA1 RNAs (Ambion) with a murine
PD-L1 cDNA probe. (E) The human PD-L1 gene was amplified by PCR from monochromosomal somatic cell hybrid genomic DNAs containing the
indicated human chromosome as well as hamster, murine, and human genomic DNAs.1032 PD-1 Ligand 1 Inhibits T Cell Activation
secretion of IFN-g and IL-10 is decreased by z80 and
60%, respectively (Fig. 4 C). IL-2 production was below
detection under these activation conditions at both 24 and
96 h. However, under conditions in which costimulation
in the form of soluble anti-CD28 is provided, activation of
cells in the presence of PD-L1 also leads to a decrease in
IL-2 production (data not shown). Thus, activation of mu-
rine and human T cells in the presence of PD-L1 leads to
inhibition of both proliferation and cytokine secretion.
The Outcome of PD-1–PD-L1 Interaction Depends on the
Strength of TCR and CD28 Signals. To examine the rela-
tionship between TCR-, CD28-, and PD-1–mediated sig-
nals, human CD41 T cells were stimulated with suboptimal
or optimal concentrations of anti-CD3 mAb, a fixed con-
centration of PD-L1.Ig, and increasing concentrations of
soluble anti-CD28 mAb. Using anti-CD3 mAb–coated
beads, the concentrations required for suboptimal and opti-
mal T cell stimulation were established (data not shown).
Under conditions of suboptimal TCR engagement (anti-
CD3 mAb at 1 mg/ml), minimal proliferation is observed
in the absence of costimulation (Fig. 5 A). The addition of
increasing concentrations of soluble anti-CD28 mAb leads
to an up to 30-fold increase in proliferation. Under these
conditions, activation of T cells in the presence of PD-L1
results in an 80% reduction in proliferation (Fig. 5 A). A
maximal level of costimulation (anti-CD28 at 250 ng/ml)
was required to rescue the inhibition of proliferation medi-
ated by PD-L1 stimulation. In contrast, under saturating
conditions of TCR activation (anti-CD3 mAb at 2 mg/ml),
PD-L1–mediated inhibition of T cell proliferation is only
observed in the absence of CD28 costimulation (Fig. 5 B).
Discussion
Recent studies of PD-1–deficient mice have revealed a
critical immunoregulatory role for this receptor, as its ab-
sence leads to autoimmunity. As PD-1 is structurally similar
to  CTLA-4, we hypothesized that the ligand of PD-1
might be a member of the B7 gene family and searched for
novel B7 homologues. One of these, later termed PD-L1,
was found to bind PD-1 specifically. The functional signif-
icance of this interaction has been demonstrated in T cell
assays, in which engagement of PD-1 by PD-L1 leads to
the inhibition of TCR-mediated lymphocyte proliferation
and cytokine secretion. PD-1 is also expressed by B cells
and myeloid cells, and the significance of PD-1 in these cell
types is evidenced by the autoantibody generation and my-
eloid hyperplasia of PD-1–deficient mice (6, 21). Thus,
PD-L1 is expected to act on a wider range of cell types
than we have demonstrated in this report.
Figure 4. TCR activation of murine and human T cells in the presence of PD-L1 results in inhibition of T cell proliferation and cytokine production.
(A) Splenic T cells from wild-type (open squares) and PD-12/2 (filled circles) C57BL/6 mice were stimulated for 72 h with varying concentrations of pre-
coated anti-CD3 Ab. (B) Splenic T cells from wild-type (squares) and PD-12/2 (circles) C57BL/6 mice were stimulated for 72 h with 10 mg/ml of anti-
CD3 mAb in combination with varying concentrations of hPD-L.Ig(g2a) (filled symbols) or control mIgG2a (open symbols). [3H]Thymidine incorpora-
tion was measured in triplicate. These data are representative of four separate experiments. (C) Purified human CD41 T cells were stimulated for 4 d with
anti-CD3 mAb/control IgG–coated beads (stippled bars), anti-CD3 mAb/hPD-L1.Ig(g2a)–coated beads (hatched bars), or medium alone (black bars).
The bead/cell ratio was 1:1. Proliferation was determined by [3H]thymidine incorporation in triplicate wells. Supernatants were collected at 96 h after ac-
tivation, and cytokine concentrations were measured using commercially available ELISA kits. The data are representative of two separate experiments.
Figure 5. TCR/PD-L1 activation in the presence
of CD28 costimulation results in inhibition of T cell
proliferation. Purified human CD41 cells were stimu-
lated for 4 d with anti-CD3 mAb/control mIgG–
coated beads (gray bars), or anti-CD3 mAb/hPD-
L1.Ig(g2a)–coated beads (black bars) in the presence of
various concentrations of soluble anti-CD28 mAb.
Stimulations were performed at (A) suboptimal (1 mg/
ml) and (B) optimal (2 mg/ml) concentrations of anti-
CD3 Ab. The bead/cell ratio was 1:1. Proliferation
was determined by [3H]thymidine incorporation in
triplicate wells. The data are representative of two sep-
arate experiments.1033 Freeman et al.
We have demonstrated that PD-L1 signaling can inhibit
the TCR-mediated proliferation of T cells. The capacity of
the PD-1–PD-L1 interaction to downregulate a CD3/
CD28-stimulated response shows that PD-1 engagement
results in the delivery of a strong inhibitory signal. How-
ever, the functional consequences of the PD-1–PD-L1 in-
teraction are dependent on the relative strength of signals
delivered via the TCR and CD28. Increasing levels of
TCR or CD28 signaling can circumvent the inhibitory ef-
fects of PD-1 ligation at the activation stage. In the absence
of the PD-1–PD-L1 interaction, the threshold of TCR sig-
nal needed for T cell activation will be lowered, consistent
with the autoimmune reactions seen in PD-1–deficient
mice (6).
In our experiments, inhibition was observed when PD-
L1 was coimmobilized with anti-CD3. This would allow
for coligation of the TCR and PD-1, consistent with the
immunoreceptor tyrosine-based inhibitory motif of PD-1
delivering a negative signal by recruitment of an Src ho-
mology 2 (SH2) domain–containing tyrosine phosphatase.
Indeed, using the A20II1.6 B lymphoma line, we have
demonstrated that cocross-linking of the B cell receptor
and PD-1 reduces the calcium influx observed by
crosslinking of the B cell receptor alone, and leads to inter-
action of the cytoplasmic region of PD-1 with SHP-2 (our
unpublished data). In addition, there is inhibition of the ty-
rosine phosphorylation of a variety of signaling molecules
leading to suppression of the proliferative response.
Dong et al. (16) have shown an increase in T cell prolif-
eration and IL-10 secretion by T cells stimulated with PD-
L1/B7-H1 and low levels of anti-CD3. Previous work has
demonstrated that PD-1 expression is not constitutive but
induced by antigen receptor cross-linking (2, 3). Thus, PD-1
would be expected to be expressed and capable of inter-
acting with PD-L1 in our assays in which the T cells are
stimulated with higher levels of anti-CD3. It is unclear
whether the PD-L1/B7-H1 costimulation reported by
Dong et al. (16) is PD-1 dependent or whether it could be
mediated by an alternative receptor for PD-L1. If a second,
costimulatory receptor exists for PD-L1, this situation
would parallel that of the costimulatory/inhibitory CD28/
CTLA-4 receptor–B7-1/B7-2 ligand pairs. We do not find
that PD-L1 induces IL-10 secretion in our assays. It should
be noted that Dong et al. find that neutralizing Ab against
IL-2 blocks the B7-H1–mediated increase in IL-10 pro-
duction, suggesting that the IL-10 production is IL-2 de-
pendent (16). Thus, the increase in IL-10 secretion may be
due to the amplification of a population of cells rather than
a direct induction.
The PD-1 gene resembles that of CTLA-4 in that it is
expressed only after T cell activation. Thus, we expect that
the PD-1–PD-L1 interaction may be most important in
setting the TCR threshold requirements at sites of restimu-
lation. Previously activated T cells that migrate to the pe-
riphery may reencounter antigen on cells expressing PD-L1
but little or no B7-1, B7-2, or other costimulatory mole-
cules. Such an interaction would fail to result in T cell ex-
pansion, except under conditions of strong TCR ligation.
In the absence of CTLA-4, mice develop a rapid and fatal
T cell proliferative disease that results in damage to multi-
ple organs (22, 23). If PD-1 ligation provides a checkpoint
for T cell activation later in an immune response than
CTLA-4 ligation, this could account for the milder pheno-
type of PD-1–deficient mice compared with CTLA-4–defi-
cient mice. Alternatively, the differences in phenotype
between mice with these null mutations may reflect differ-
ences in the expression patterns of their respective ligands.
The expression patterns of B7-1, B7-2, and PD-L1 are
distinct. B7-2, one of the ligands of CD28 and CTLA-4, is
constitutively expressed on monocytes; however, constitu-
tive expression of B7-1 and B7-2 is not seen in any organ.
B7-1 and B7-2 expression can be induced in dendritic cells,
macrophages, and B cells (15), as well as some types of fi-
broblast and epithelial cell. In contrast, PD-L1 is expressed
constitutively by nonlymphoid, parenchymal organs such as
the heart, placenta, skeletal muscle, and lung, but not the
small intestine (16; Fig. 3 D). PD-L1 is also expressed in
some cancers, as three ESTs are from human ovarian tu-
mors. This raises the possibility that some tumors may use
PD-L1 to inhibit an antitumor immune response. We
found that PD-L1 expression by monocytes and kerati-
nocytes was enhanced by stimulation with IFN-g. Upon
activation, keratinocytes express MHC class II, but not
B7-1 or B7-2 (24). Induction of PD-L1 expression by cy-
tokines such as IFN-g or other inflammatory stimuli could
result in attenuation of TCR/CD28–mediated T cell acti-
vation. This may be of particular significance in the effector
sites of inflammatory or autoimmune responses. As PD-1 is
expressed on activated T as well as B cells (2), the expres-
sion of PD-L1 in nonlymphoid tissues as well as on den-
dritic cells may allow for regulation of potentially autoreac-
tive lymphocytes at sites of immune activation as well as at
effector sites. This may be a particularly important mecha-
nism in limiting activities of both T and B cells in the heart,
lung, kidney, and placenta where PD-L1 is highly ex-
pressed. In this context, Fas-L, a potent immune negative
regulator, is also expressed on nonlymphoid tissues includ-
ing the small intestine and testis (25). Interestingly, the tis-
sue expression patterns of PD-L1 and Fas-L appear to be in
general mutually exclusive, suggesting nonredundant regu-
lation of peripheral tolerance by the Fas–Fas-L and PD-1–
PD-L1 pathways.
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